Related Experiment Video
Updated: Jun 20, 2026

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
Published on: October 18, 2018
Pharmacological effects of carvedilol on T-type calcium current in murine HL-1 cells
Chunyu Deng1, Fang Rao, Shulin Wu
1Medical Research Center of Guangdong General Hospital, Guangzhou, PR China.
Insights
Carvedilol inhibits T-type calcium channels (I(Ca,T)) in atrial cells, impacting calcium transients. This drug affects channel inactivation and recovery, suggesting a new mechanism for its cardiovascular effects.
Area of Science:
- Cardiovascular Pharmacology
- Ion Channel Physiology
- Cardiac Electrophysiology
Background:
- Carvedilol is a cardiovascular drug used for conditions like atrial fibrillation.
- T-type calcium channels (I(Ca,T)) are implicated in atrial arrhythmias.
- The effect of carvedilol on T-type calcium channels was previously unknown.
Purpose of the Study:
- To investigate the pharmacological effects of carvedilol on T-type calcium current (I(Ca,T)).
- To determine if carvedilol influences calcium transients in atrial cells.
Main Methods:
- Whole-cell patch-clamp technique to record I(Ca,T) in murine HL-1 cells.
- Confocal laser scanning microscopy and Fluo-4/AM to monitor calcium transients.
- Concentration-dependent analysis and assessment of channel kinetics.
Main Results:
- Carvedilol inhibited I(Ca,T) concentration-dependently (IC50 = 2.1 microM).
- Carvedilol shifted inactivation curves negatively and delayed recovery from inactivation.
- Inhibition of I(Ca,T) and calcium transients was observed, frequency-dependent.
Conclusions:
- Carvedilol inhibits T-type calcium current in atrial cells.
- The mechanism involves preferential interaction with the inactivated state of T-type Ca(2+) channels.
- This action may contribute to carvedilol's therapeutic effects in cardiovascular diseases.
Abstract:
Carvedilol is widely used in the treatment of cardiovascular diseases including atrial fibrillation. T-type Ca(2+) channels have been recognized recently in the mechanisms underlying atrial arrhythmias. However, it is unclear whether carvedilol may affect the T-type Ca(2+) channel. The present study evaluated the pharmacological effects of carvedilol on T-type calcium current (I(Ca,T)) in the murine HL-1 cell line. I(Ca)(,T) was recorded by the whole-cell patch-clamp technique. Calcium transient was monitored by the fluorescent dye Fluo-4/AM and confocal laser scanning microscopy. Carvedilol reversibly inhibited I(Ca)(,T) in a concentration-dependent manner, with an IC50 of 2.1 microM. 3 microM carvedilol was found to decrease the peak I(Ca)(,T) amplitude at -20 mV from 20.1+/-1.8pA/pF to 10.9+/-2.1pA/pF. Carvedilol significantly shifted the steady-state inactivation curve of I(Ca)(,T) towards more negative potential by 12.8 mV, while the activation curve was not significantly altered. Carvedilol delayed recovery from inactivation of I(Ca)(,T), time constant (tau) was 112.4+/-3.5 ms in control and 270.1+/-4.7 ms in carvedilol. Carvedilol-induced inhibition rate in I(Ca)(,T) was enhanced with the increase in stimuli frequency, the inhibitory rate was 23.2+/-4.1% at 0.2 Hz and 47.2+/-0.6% at 2 Hz. Carvedilol still produced the significant decrease in the amplitude of I(Ca)(,T) in the presence of H-89, PKA inhibitor. Carvedilol significantly inhibited the amplitude of the calcium transient in a concentration-dependent manner. These findings indicate that carvedilol inhibits I(Ca)(,T) in atrial cells by mechanisms involving preferential interaction with the inactivated state of T-type Ca(2+) channel.
More Related Videos
Related Concept Videos
Antihypertensive Drugs: Action of Calcium Channel Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

